These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27273032)

  • 21. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.
    Montandon SV; Fajt ML; Petrov AA
    Curr Drug Saf; 2016; 11(2):145-8. PubMed ID: 26647917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P; Dahlerup JF
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease and anemia: intravenous iron treatment.
    Kangaspunta M; Haapamäki J; Färkkilä M; Arkkila P
    Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial.
    Laso-Morales MJ; Vives R; Vallejo-Tarrat A; Caló N; Valle-Beltran A; Pontes C
    Trials; 2019 Jan; 20(1):23. PubMed ID: 30616657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaemia tolerance: bridging with intravenous ferric carboxymaltose in a patient with acute post-haemorrhagic anaemia.
    Hönemann CW; Doll D; Kampmeier T; Ertmer C; Hagemann O; Hahnenkamp K
    Br J Anaesth; 2012 Jan; 108(1):167-8. PubMed ID: 22157459
    [No Abstract]   [Full Text] [Related]  

  • 27. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF; Muduma G
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Iron deficiency anemia and anemia of chronic disease (ACD)].
    Hiller E
    Dtsch Med Wochenschr; 2014 May; 139(22):1163-70; quiz 1171-4. PubMed ID: 24809951
    [No Abstract]   [Full Text] [Related]  

  • 29. Resurrecting the iron age*.
    Shander A; Javidroozi M
    Crit Care Med; 2012 Jul; 40(7):2252-3. PubMed ID: 22710223
    [No Abstract]   [Full Text] [Related]  

  • 30. Progress in intravenous iron treatment.
    Marx JJ
    Arzneimittelforschung; 2010; 60(6a):341-4. PubMed ID: 20648925
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron supplementation in a case of severe iron deficiency anaemia.
    Füllenbach C; Triphaus C; Glaser P; Ziebart A; Zacharowski K; Meybohm P; Choorapoikayil S
    Br J Anaesth; 2018 Aug; 121(2):502-504. PubMed ID: 30032895
    [No Abstract]   [Full Text] [Related]  

  • 32. Iron deficiency: the hidden miscreant in inflammatory bowel disease.
    Allocca M; Fiorino G; Danese S
    Curr Drug Targets; 2014; 15(11):1011-9. PubMed ID: 25213175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron.
    Powers JM; Shamoun M; McCavit TL; Adix L; Buchanan GR
    J Pediatr; 2017 Jan; 180():212-216. PubMed ID: 27776750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring iron therapy in chronic heart failure.
    Weiss G
    Eur J Heart Fail; 2013 Jul; 15(7):711-2. PubMed ID: 23794608
    [No Abstract]   [Full Text] [Related]  

  • 36. Preventing skin staining: an effective iron infusion protocol.
    Crowley CM; McMahon G; Desmond J; Imcha M
    Int J Health Care Qual Assur; 2020 Mar; ahead-of-print(ahead-of-print):. PubMed ID: 32162854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
    Froessler B; Gajic T; Dekker G; Hodyl NA
    Arch Gynecol Obstet; 2018 Jul; 298(1):75-82. PubMed ID: 29740690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Iron deficiency : a new target in treating chronic heart failure ?].
    Borgeaud M; Perrier A
    Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
    Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ferric Carboxymaltose: A Review in Iron Deficiency.
    Scott LJ
    Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.